Early clinical data reveal Johnson & Johnson's dual-targeting CD19/CD20 CAR-T therapy achieving up to 100% response rates in some lymphoma patients, while menin inhibitor combination therapy in acute myeloid leukemia shows promising remission and safety in phase 1 trials. These developments highlight continued progress in precision immunotherapy approaches targeting hematologic malignancies with genetic subtyping and combination drug regimens.